Join

Compare · NTRA vs TLSI

NTRA vs TLSI

Side-by-side comparison of Natera Inc. (NTRA) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NTRA and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
  • NTRA is the larger of the two at $31.91B, about 155.6x TLSI ($205.1M).
  • Over the past year, NTRA is up 33.2% and TLSI is down 37.5% - NTRA leads by 70.8 points.
  • NTRA has been more active in the news (18 items in the past 4 weeks vs 8 for TLSI).
  • NTRA has more recent analyst coverage (25 ratings vs 6 for TLSI).
PerformanceNTRA+33.23%TLSI-37.55%
2025-06-10+0.00%2026-06-10
MetricNTRATLSI
Company
Natera Inc.
TriSalus Life Sciences Inc.
Price
$220.03-1.27%
$3.46+3.59%
Market cap
$31.91B
$205.1M
1M return
+10.42%
-23.96%
1Y return
+33.23%
-37.55%
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NASDAQ
IPO
2015
2021
News (4w)
18
8
Recent ratings
25
6
NTRA

Natera Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Latest NTRA

Latest TLSI